Promis Neurosciences (PMN) – Investment Analysts’ Weekly Ratings Changes

Promis Neurosciences (NASDAQ: PMN) recently received a number of ratings updates from brokerages and research firms:

• 7/18/2026 – Promis Neurosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/15/2026 – Promis Neurosciences had its “buy” rating reaffirmed by HC Wainwright.
• 7/7/2026 – Promis Neurosciences is now covered by Roth Capital. They set a “buy” rating and a $19.00 price target on the stock.
• 7/7/2026 – Promis Neurosciences was upgraded by Roth Capital to “strong-buy”.
• 6/30/2026 – Promis Neurosciences is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 6/24/2026 – Promis Neurosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 6/20/2026 – Promis Neurosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 6/11/2026 – Promis Neurosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/9/2026 – Promis Neurosciences was upgraded by Zacks Research to “hold”.
• 6/8/2026 – Promis Neurosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 5/31/2026 – Promis Neurosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.

Promis Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small?molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.